Autologous Dendritic Cell–Tumor Antigen Vaccine Shows Clinical Benefit in Glioblastoma
A vaccine consisting of autologous dendritic cells exposed to tumor antigens was well tolerated and showed clinical benefit among patients with glioblastoma.
A vaccine consisting of autologous dendritic cells exposed to tumor antigens was well tolerated and showed clinical benefit among patients with glioblastoma.
A study evaluated characteristics of pseudoprogression among patients with cervical cancer treated with ICIs.
A neoantigen vaccine administered in the adjuvant setting to patients with different cancer types was well tolerated and generated a T-cell response .
Use of dexamethasone was associated with shorter survival in those with glioblastoma treated with a PD-1/PD-L1 inhibitor.
BEMPEG combined with nivolumab resulted in deep and durable responses among patients with treatment-naive metastatic melanoma, according to phase 2 data.
NIZ985, a heterodimer of IL-15 and IL-15α, showed antitumor activity when combined with spartalizumab among patients with pretreated, advanced solid tumors, in a phase 1 study.
NKTR-262 enhances antigen presentation and demonstrated early efficacy and a tolerable safety profile in combination with bempegaldesleukin in pretreated advanced solid tumors.
Bemcentinib, an AXL inhibitor, was tolerable and demonstrated antitumor activity in combination with pembrolizumab in AXL-positive, relapsed NSCLC.